Why I feel buying the AstraZeneca share price could destroy your retirement riches

Roland Head explains why he’s avoiding AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Buying shares in bad businesses may be the most obvious way to lose money in the stock market.

But there’s another way of losing money that’s almost as dangerous and is often overlooked. I’m talking about valuation. Paying too much for a stock can leave you sitting on a loss for years, while the wider market steams ahead.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

The two companies I’m looking at today are good businesses, but they look too expensive to me.

Pharma buzz

FTSE 100 pharmaceutical firm AstraZeneca (LSE: AZN) may seem an unlikely choice for this article. Surely this company is conservatively valued, produces reliable profits and pays a generous dividend?

Unfortunately, this isn’t the case. AZN shares have risen by 47% over the last five years to an all-time high of more than £63, despite falling profits and rising debt.

This has left the group trading on 22.2 times 2019 forecast adjusted earnings, with a dividend yield of 3.5% — well below the FTSE 100 average of 4.3%.

In my view, this valuation is pricing in a lot of future progress. I’m also concerned that the company’s preferred measure of adjusted earnings may be flattering its performance, something my colleague G A Chester covered recently in more detail.

Worse than it looks?

Over the last four years, AstraZeneca’s net debt has risen from $7.8bn to $16.3bn. I believe one reason for this is the maintenance of the group’s $2.80 per share dividend.

You see, the company has paid out about $14bn in cash distributions to shareholders since 2015, but has only reported shareholder profits of $11.5bn.

These numbers tell me that Astra is relying heavily on borrowed cash to fund investments in new medicines, while paying out all of its profits (and more) to shareholders.

The situation reached a new low in March, when Astra decided to raise $3.5bn from shareholders just days after paying a dividend of $2.4bn. This seems ludicrous to me — if cash really is that tight, the dividend should be cut.

My verdict: AstraZeneca has an exciting pipeline of new products, but I think the price is far too high, given the group’s weak cash generation and steep valuation. I’d wait for a better opportunity to buy.

Down 13% as spending climbs

My next stock also operates in the pharmaceutical sector, producing antibodies for research labs. Shares in Abcam (LSE: ABC) have risen from about 140p to 1,221p over the last 10 years, valuing this business at over £2.5bn.

However, the stock is down by more than 14% at the time of writing. Today’s fall came after the company announced plans to increase spending on expansion and said its chief financial officer had resigned.

Slowdown?

I should explain that Abcam has delivered high profit margins and strong growth for some years. Profits doubled between 2013 and 2018, for example.

However, earnings per share for the year that ended on 30 June are expected to be broadly unchanged from the previous year. Looking ahead, analysts expect modest earnings growth of 7% for the current year.

With spending rising, it’s not clear to me whether Abcam will be able to maintain its historic operating profit margin of nearly 30%. This risk — plus slower growth — suggests to me that the stock’s forecast price/earnings ratio of 35 is rather high.

As with AstraZeneca, I think this is a good business, but in my view it’s too expensive at the moment.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Abcam and AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Retirement Articles

Hand holding pound notes
Investing Articles

Why I’d forget savings accounts and buy dividend stocks today!

Although I hold 'rainy day' money in a cash savings account, I prefer buying shares to try to grow my…

Read more »

Retirement saving and pension planning
Investing Articles

State Pension age to rise to 68? I’m buying UK shares to try to protect myself!

It's important for me to find ways to make money as the State Pension age rises. Here's why I'm choosing…

Read more »

Couple relaxing on a beach in front of a sunset
Investing Articles

Not saving enough for retirement? 2 FTSE 100 shares I’d buy to try and retire comfortably

I believe I've found the best way to try and build a big nest egg so I can retire in…

Read more »

Retirement saving and pension planning
Investing Articles

How I’m aiming to double my State Pension with just £30 a week

After making regular monthly investments while earning an average salary, this man is planning to retire early. Here's how.

Read more »

Happy retired couple on a beach
Investing Articles

Investing at 60: how I’ll handle shares in my financial autumn

Investing at 60-plus doesn't have to be dull! This is how I plan to keep on aiming to build wealth…

Read more »

Retirement saving and pension planning
Retirement Articles

State Pension: should I buy UK shares to retire in comfort?

Worries about the State Pension are soaring as chatter over the scrapping of the triple lock grows. Could buying UK…

Read more »

Investing Articles

ISA investing: here’s why I’m buying UK shares to retire in comfort!

We're all looking to build a handsome nest egg for retirement, right? Well this is how I'm using ISAs so…

Read more »

Lady researching stocks
Investing Articles

ISA investing: 3 of the best stocks to buy in May

I'm scouring UK share markets to find some of the best stocks to buy for May. Here are three I'm…

Read more »